Wells Fargo raised the firm’s price target on AbbVie to $200 from $180 and keeps an Overweight rating on the shares. The firm says AbbVie’s growth story is looking better as Skyrizi and Rinvoq are poised to overtake Humira, and pipeline is emerging with internal assets and BD. AbbVie has shown it can manage Humira erosion, and the focus is now on delivering growth through the 2030s, Wells adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV: